Kinase Inhibitor News and Research

RSS

A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.

Combo of targeted and immunotherapy may boost NSCLC treatment by overcoming immune resistance and enhancing anti-tumor activity

Researchers evaluated rational combination treatment regimens for advanced/metastatic non-small-cell lung cancer (NSCLC).

15 Feb 2024

Combination therapy offers breakthrough in NSCLC treatment

A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center.

13 Feb 2024

Hope for relapsed myeloma: Preclinical and clinical evidence for ruxolitinib's efficacy

A new research perspective was published in Oncotarget's Volume 15 on February 5, 2024, entitled, "Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma."

8 Feb 2024

Pazopanib activity confirmed in EWSR1-NFATC2 bone sarcoma

A new case report was published in Oncoscience (Volume 10) on September 20, 2023, entitled, "Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma."

12 Jan 2024

Glioblastoma tumor cells mimic neurons to evade treatment

Certain cancers are more difficult to treat because they contain cells that are highly skilled at evading drugs or our immune systems by disguising themselves as healthy cells.

11 Jan 2024

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at The University of Texas MD Anderson Cancer Center.

11 Dec 2023

Fecal microbiota transplantation boosts survival in metastatic colorectal cancer treatment

A recent study in eClinicalMedicine found that fecal microbiota transplantation, combined with fruquintinib and tislelizumab, significantly improved survival rates in patients with microsatellite stable metastatic colorectal cancer, showing manageable safety and notable increases in progression-free and overall survival.

15 Nov 2023

Unraveling the role of HER2 mutant alleles in breast cancer

A new editorial paper was published in Oncotarget's Volume 14 on October 31, 2023, entitled, "The uncharted role of HER2 mutant alleles in breast cancer."

6 Nov 2023

Using ripretinib and surgery to manage recurrent gastrointestinal stromal tumor

A new case report was published in Oncoscience (Volume 10) on September 20, 2023, entitled, "Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery."

3 Nov 2023

New treatment breakthrough: Pyrotinib combo demonstrates remarkable efficacy for HER2 positive metastatic breast cancer

The safety and efficacy of treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with pyrotinib.

2 Nov 2023

New blood test pinpoints Parkinson's disease through mitochondrial DNA damage

Researchers have developed a new blood test that measures mitochondrial DNA damage as a potential marker for Parkinson's disease (PD). The study shows the test could aid in diagnosing PD and assessing responses to LRRK2 kinase inhibitors, which may help in reducing mitochondrial damage in PD patients.

4 Sep 2023

Combination of cediranib and lenalidomide does not improve outcomes in advanced thyroid cancer

Results of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show that adding an immunomodulatory agent to treatment with the targeted tyrosine kinase inhibitor (TKI) cediranib did not make a difference in outcomes for treating patients with an advanced form of thyroid cancer that develops from thyroid follicular cells called differentiated thyroid cancer (DTC).

1 Sep 2023

Parkinson's disease diagnosis could be made earlier with new blood test

Researchers have developed a blood test that detects Parkinson's disease, potentially establishing a way to help diagnose the condition before nervous system damage worsens.

30 Aug 2023

KIPA shows promise in predicting chemotherapy response in triple negative breast cancer

Researchers at Baylor College of Medicine and collaborating institutions are developing a strategy to predict the response of triple negative breast cancer (TNBC) to chemotherapy, which would be a valuable tool for physicians deciding on the treatment with better probability of success on an individual basis.

21 Jul 2023

$Fruquintinib improved survival in patients with refractory metastatic colorectal cancer$

Fruquintinib improved survival in patients with refractory metastatic colorectal cancer

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer.

16 Jun 2023

New method can kill aggressive brain tumors

Researchers at the University of Gothenburg, working with French colleagues, have successfully developed a method able to kill the aggressive brain tumor glioblastoma.

25 May 2023

Anticoronavirals: the development of COVID-19 therapies and the challenges that remain

Researchers highlighted the pace of development of COVID-19 therapies during the pandemic and the challenges that hinder the widespread availability of anticoronavirals.

8 May 2023

Study investigates how loss of angulin-1/LSR affects the malignancy of lung adenocarcinoma

A new research paper was published in Oncotarget's Volume 14 on March 24, 2023, entitled, "Downregulation of angulin-1/LSR induces malignancy via upregulation of EGF-dependent claudin-2 and TGF-β-dependent cell metabolism in human lung adenocarcinoma A549 cells."

29 Mar 2023

One-Pot-LAMP: A promising tool for non-small cell lung cancer diagnosis

Researchers assessed the efficiency of a genetic decoding system for diagnosing non-small cell lung cancer (NSCLC).

16 Mar 2023

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

Ipsen (Euronext: IPN; ADR: IPSEY) today announced three-year minimum, 44-month median, follow-up results from the Phase III CheckMate -9ER trial showing that Cabometyx® (cabozantinib) in combination with nivolumab provides survival and response rate benefits after three-years in the first-line treatment of advanced renal cell carcinoma (aRCC), compared to sunitinib.

From Ipsen 14 Feb 2023